A Study of CS3005 in Advanced Solid Tumors

CStone Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Advanced Solid Tumor

Treatments

Drug: CS3005

Study type

Interventional

Funder types

Industry

Identifiers

NCT04233060

CS3005-101

Details and patient eligibility

About

A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects with Advanced Solid Tumors

Enrollment

9 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

General

Be willing and able to provide written informed consent form for the trial.
Male or female between 18 to 75 years of age.
Ability to comply with requirements of the protocol, as assessed by the investigator.
Subjects who were histologically confirmed advanced solid tumor shall have progressed disease and/or experienced intolerance from prior standard therapies, or for whom no standard of care (SoC) therapies exist.
Subject must have at least one measurable lesion by CT or MRI; radiographic tumor assessment should be performed within 28 days prior to the first dose of study treatment.
ECOG performance status score of 0 or 1
Prior immunotherapy is allowed
Subjects who have previously received anti-tumor therapy will only be enrolled if the toxicities from the previous treatment have returned to the baseline level or NCI CTCAE v 5.0 grade ≤1.
Subject must have adequate organ function as indicated by the following laboratory values, G-CSF or other relevant medical support within 14 days before the administration of the investigational product
Subjects with active hepatitis B or active hepatitis C must receive antiviral treatment and pass the HBV DNA titer test and HCV RNA test before being enrolled. The subject should be willing to continue effective anti-viral treatment during the study.
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result. Either Female or male subjects must agree to use adequate contraceptive measures.

Exclusion Criteria:

Has disease that is suitable for local treatment administered with curative intent
Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
Patients with any condition that impairs their ability to take oral medication.
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Subjects with active, known, or suspected autoimmune disease in the past 3 years prior to the start of treatment.
History of active tuberculosis, both pulmonary and extrapulmonary.
Clinically Significant history of cardiac disease within 6 months prior to 1st dosing, myocardial infarction within the previous year, or current cardiac ventricular arrhythmias requiring medication.
Subjects with ascites, pleural effusion, pericardial effusion which cannot be reversed by appropriate interventions.
Subjects with any active infections requiring systemic therapy within 2 weeks prior to the initiation of the study treatment.
Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.
History of organ transplant that requires the use of immunosuppressive treatment.
For post immunotherapy patients, with prior ≥ Grade 3, serious, or life-threatening immune-mediated reactions following prior anti-PD-(L)1 or other immune-oncology therapies.
Subjects who have received systemic anti-tumor treatments 21 days prior to the initiation of the study treatment.
Subjects who have received treatment with approved anti-tumor Chinese herbal medicine or Chinese prepared.
Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications.
Has received treatment with non-selective adenosine antagonist or A2a receptor antagonist.
Concurrent administration of strong inhibitors or inducers of CYP3A4 and CYP1A2 is not permitted